Clinical Trials
352
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (305 trials with phase data)• Click on a phase to view related trials
A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)
- Conditions
- HCC
- Interventions
- Drug: lparomlimab and Tuvonralimab Injection in Combination with HAIC and bevacizumab
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Target Recruit Count
- 34
- Registration Number
- NCT07119931
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
- Conditions
- Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCTNewly Diagnosed Multiple Myeloma (NDMM)
- Interventions
- Drug: BCMA/CD19-targeted allogeneic CAR-T
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Target Recruit Count
- 19
- Registration Number
- NCT07114432
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
🇨🇳Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma Following Failure of First-Line Systemic Therapy
- Conditions
- HCC
- Interventions
- Drug: lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-08-01
- Target Recruit Count
- 29
- Registration Number
- NCT07099274
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Induction Immunotherapy Combined With Chemotherapy Followed by Concurrent Chemoradiotherap and Immunotherapy for Cervical Cancer
- Conditions
- Cervical Cancer
- Interventions
- Radiation: Pelvic External-Beam Radiotherapy (EBRT)
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Target Recruit Count
- 34
- Registration Number
- NCT07092696
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute&Hospital, Tianjin, China
The Efficacy and Safety of First-line Treatment Combined With Immunotherapy for Advanced Hepatocellular Carcinoma: a Single Center, Real-world Study
- Conditions
- Hepatocellular Carcinoma (HCC)Real World Study
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Target Recruit Count
- 400
- Registration Number
- NCT07078292
- Prev
- 1
- 2
- 3
- 4
- 5
- 71
- Next
News
Chinese Drug Combination Outperforms Keytruda in Advanced Lung Cancer Trial
A Chinese-developed drug combination of Benmelstobart and Anlotinib demonstrated superior efficacy over pembrolizumab (Keytruda) in treating PD-L1-positive advanced non-small cell lung cancer patients.
Phase 2 Trial Shows Promise: Camrelizumab Plus Chemotherapy Effective for Advanced Nasopharyngeal Cancer in Non-Endemic Regions
A phase 2 trial demonstrates that combining camrelizumab immunotherapy with induction chemotherapy and chemoradiotherapy achieved an 84% 3-year disease-free survival rate in advanced nasopharyngeal cancer patients.
Pyrotinib Plus Metronomic Vinorelbine Shows Efficacy in HER2+ Advanced Breast Cancer Post-Trastuzumab
A phase 2 trial in China demonstrated that pyrotinib combined with metronomic vinorelbine is effective in HER2-positive advanced breast cancer patients after trastuzumab failure.